Search clinical trials for: First line therapy

Total 70538 results

Fondazione del Piemonte per l'Oncologia

Completed

A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP) (AGNOSTOS)

Unknown Primary Tumors

Italy
University Health Network, Toronto
Bayer

Active, not recruiting

Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC (TRANCE)

Metastatic Prostate Cancer

Canada
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids (MTX-aGVHD)

Stem Cell Transplant Complications | GVHD, Acute | GVH - Graft Versus Host Reaction | Allogeneic Disease

France
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment

Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Colon Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IIA Rectal Cancer AJCC... and other conditions

United States
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)

Renal Cell Carcinoma

Japan
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread

Urothelial Carcinoma

Japan
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

Carcinoma, Hepatocellular

United States, Australia, Canada, Chile, China, Colombia, France, Germany, Ireland, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Russian Federation, Spain, Taiwan, Thailand, Turkey, United Kingdom
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Nausea | Constipation | Diarrhea | Purpura | Lymphadenopathy | Gastrointestinal Hemorrhage | Hepatomegaly | Primary Systemic Amyloidosis | Amorphous, Eosinophilic, and Acellular Deposit | Early Satiety | Macroglossia | Recurrent Primary Amyloidosis | Refractory Primary Amyloidosis

United States
GERCOR - Multidisciplinary Oncology Cooperative...

Active, not recruiting

QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters. (COLAGE)

Quality of Life | Metastatic Colorectal Cancer | Elderly Patients

France
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); NCIC Clinical Trials Group; Cancer and Leukemia... and other collaborators

Active, not recruiting

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (SOFT)

Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Positive Breast Cancer | Progesterone Receptor Positive Tumor

United States, Canada, Switzerland
Daehwa Pharmaceutical Co., Ltd.

Active, not recruiting

Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy (OPTIMAL)

Recurrent or Metastatic Breast Cancer

China, Korea, Republic of, Serbia, Bulgaria, Hungary
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)

Breast Cancer

United States, Puerto Rico
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States, Canada, Israel, Puerto Rico
University of Utah

Completed

Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy

Melanoma
Celgene

Completed

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Spain, Australia, Austria, Bulgaria, Canada, China, Colombia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Israel, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Se... and more
Novartis Pharmaceuticals

Completed

Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia (SOAR)

Severe Aplastic Anemia

Spain, Italy, Hong Kong, Thailand, Korea, Republic of, Mexico, Turkey, India, Brazil
Sanofi

Terminated

Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (AMEERA-5)

Breast Cancer

United States, Russian Federation, Italy, Australia, Belgium, France, Japan, Ukraine, Netherlands, Argentina, Canada, Portugal, Spain, Austria, Brazil, Bulgaria, Chile, China, Czechia, Finland, Georgia, Germany, Hungary, Korea, Republic... and more
Menoufia University

Completed

Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients

Radiation Therapy | Non-Small Cell Carcinoma of Lung, TNM Stage 4

Egypt
Pfizer

Completed

Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)

Renal Cell Carcinoma

Japan
SCRI Development Innovations, LLC
Celgene

Terminated

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

Transitional Cell Carcinoma | Bladder Cancer | Urothelial Carcinoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.; Celgene Corporation

Active, not recruiting

Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma

Multiple Myeloma in Relapse

United States
Chinese PLA General Hospital
The Second Hospital of Hebei Medical University; Air Force Military Medical... and other collaborators

Completed

First Line Therapy for High Risk Acute GVHD

Stem Cell Transplant Complications | aGVHD

China
Huazhong University of Science and Technology
Peking University People's Hospital; West China Hospital; Ruijin Hospital

Completed

ASCT Versus Chemotherapy as First-Line Consolidation Therapy inT-Cell Lymphoma

T-cell Lymphoma Adults
iOMEDICO AG

Completed

Non-interventional Study of Lenalidomide / Dexamethasone as First Line Therapy in Patients With Multiple Myeloma (FIRST-NIS)

Multiple Myeloma

Germany
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread (CheckMate 9X8)

Colorectal Cancer

United States, Puerto Rico, Canada, Japan, Spain
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Active, not recruiting

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy. (SOLSTICE)

Metastatic Colorectal Cancer

United Kingdom, Lithuania, France, Sweden, Australia, Latvia, Spain, Poland, Argentina, Austria, Brazil, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, Ireland, Italy, Netherlands, Portugal, Romania, Russian Federation, Slovakia, Ukrai...
MedImmune LLC

Terminated

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Metastatic Microsatellite-stable Colorectal Cancer

United States, Spain, France, Australia, Canada
Pfizer
In Expanded Access, treating physicians are the Sponsors

Available

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Metastatic Castration-Resistant Prostate Cancer
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian... and other conditions

United States, Puerto Rico
University of Michigan Rogel Cancer Center
Exelixis

Active, not recruiting

Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy

Advanced Adult Hepatocellular Carcinoma

United States
Kite, A Gilead Company

Completed

Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (ZUMA-12)

B-cell Lymphoma

United States, Australia, France
Shen Feng

Active, not recruiting

Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC

Intrahepatic Cholangiocarcinoma

China
National Cancer Institute (NCI)

Completed

Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

Stage III Soft Tissue Sarcoma AJCC v7 | Stage IV Soft Tissue Sarcoma AJCC v7 | Pleomorphic Liposarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Metastatic Unresectable Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue Sarcoma | Metastatic... and other conditions

United States
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Metastatic Prostate Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage IV Renal... and other conditions

United States, Puerto Rico
Yonsei University

Completed

Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy

HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer

Korea, Republic of
AstraZeneca

Completed

Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy (PISCES)

Locally Advanced or Metastatic NSCLC

China
Oana Danciu, MD
Pfizer; Big Ten Cancer Research Consortium

Active, not recruiting

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

Metastatic Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Estrogen Receptor Positive Breast Cancer | Progesterone Receptor Positive Tumor

United States
University of Nebraska
National Cancer Institute (NCI); Spectrum Pharmaceuticals, Inc

Completed

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-cell Lymphoma

United States
ppharmaand GmbH
Bristol-Myers Squibb; Gynecologic Oncology Group; European Network of Gynaecological... and other collaborators

Active, not recruiting

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response

United States, United Kingdom, Korea, Republic of, Russian Federation, Canada, Denmark, Taiwan, New Zealand, Ireland, Japan, Spain, Australia, Israel, Italy, Greece, Sweden, Czechia, Finland, Poland, Belgium, Germany, Romania, Singa... and more
PCI Biotech AS

Terminated

PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer (RELEASE)

Cholangiocarcinoma

United States, Spain, Belgium, Germany, Italy, Denmark, Finland, France, Korea, Republic of, Norway, Poland, Sweden, Taiwan, Ukraine
National Cancer Institute (NCI)
NRG Oncology

Completed

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IB Esophageal Cancer AJCC v7

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Suspended

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Invasive Breast Carcinoma | HER2/Neu Negative | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIC Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Canadian Cancer Trials Group; Division of Cancer... and other collaborators

Active, not recruiting

Breast Cancer WEight Loss Study (BWEL Study)

Breast Carcinoma

United States, Canada, Puerto Rico, Guam
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast Carcinoma

United States, Puerto Rico
RenJi Hospital

Active, not recruiting

Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer

Stomach Neoplasms

China
Canadian Myeloma Research Group
Merck Sharp & Dohme LLC

Withdrawn

A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

Multiple Myeloma

Canada
Edward Kim
Bristol-Myers Squibb; National Cancer Institute (NCI)

Terminated

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditions

United States
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma (JS001)

Metastatic Melanoma | Unresectable Melanoma

China
Borstkanker Onderzoek Groep

Active, not recruiting

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

Breast Neoplasm Female

Netherlands
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Active, not recruiting

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States, Canada, Israel, Hong Kong, Singapore, Switzerland

Search clinical trials for: First line therapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations